Stock listing

Kodiak Sciences Inc

Selected listing: KOD · BMV · MXN · MX

Kodiak Sciences Inc (BMV:KOD), Health Technology. Latest release Sep 28, 2026: Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial…

KOD:BMVMXNMXUpdated September 25, 2026

Ticker: BMV:KOD
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: BMV
Currency: MXN

About Kodiak Sciences Inc

The company focuses on developing innovative therapies for eye diseases. Kodiak is committed to advancing its research and product pipeline to address unmet medical needs in ophthalmology.

Latest news from Kodiak Sciences Inc

Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.

September 28, 2026

Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

September 25, 2026

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results

August 13, 2026

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

August 10, 2026

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

August 6, 2026

All Kodiak Sciences Inc news →

Research Kodiak Sciences Inc

Kodiak Sciences Inc company profile

View the public company page for Kodiak Sciences Inc on 6ix.

Kodiak Sciences Inc news

Read company news and market updates connected to Kodiak Sciences Inc.

Kodiak Sciences Inc investor events

Find investor webinars, events, and replay context for Kodiak Sciences Inc.